10000 news items
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEVA
1 Jun 24
Report on Form 10-K for the year ended December 31, 2023, including in the section captioned "Risk Factors." Forward-looking statements speak only
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEVA
1 Jun 24
in our Quarterly Report on Form 10-Q for the first quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including
Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.
AKRO
1 Jun 24
, Akero filed with the SEC a Form 8-K which reported the 24-week results for Akero's Phase 2b HARMONY study of EFX in patients with pre-cirrhotic NASH
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BDTX
1 Jun 24
of the forward-looking statements include those risks and uncertainties set forth in its Annual Report on Form 10-K for the year ended December 31, 2023
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho
QDEL
1 Jun 24
, effective February 21, 2024. Then, on April 2, 2024, QuidelOrtho announced that it had withdrawn its FDA 510(k) submission for approval to sell the Savanna
gfvjqcb rz0t51arhb03jienwzeaeky0sgxcn4sntq1d4jku
CLPT
1 Jun 24
of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the three months
7szi0w vzxs3s
HRBR
1 Jun 24
disclosures as of and for the year ended December 31, 2022 contained in the Company's Annual Report on Form 10-K, (ii) interim consolidated financial
isqs4gq88fjw81ab01qrpalz2 9huf0bryfbuzreq5d
YMAB
1 Jun 24
the Company including those described in the "Risk Factors" section included in the Company's Annual Report on Form 10-K for the fiscal year
j5wkggjuemxnq0i5 m8euuy
JAZZ
1 Jun 24
(Commission File No. 001-33500), including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended
nybotmla6s2x6k4ln86x 6ox9jkm1an5fiod
YMAB
1 Jun 24
on Form 10-K for the fiscal year ended December 31, 2023, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future
bs5rgagk1t88hijibunie d5pvx1retz3484z3ltmbjc2u
IMCR
1 Jun 24
and Exchange Commission, including Immunocore's most recent Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities
as7tm6w96zo jmr0cat7liysz2gkbc83j8gjbbjr4yk2tqr4an
BMY
1 Jun 24
in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2023
dc8o 1m7fjbpwfg0dj2zp96i8u74fw5n6j2tar34w
PFE
TAK
1 Jun 24
Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned
ur7nz9x4i48dxt5mgpxsho9z6ddfu2fabqn9knze56934fj 4pc1a4ket
KYMR
1 Jun 24
in greater detail in the section entitled "Risk Factors" in the Annual Report on Form 10-K for the period ended December 31, 2023, as well
9csh0ghbkh5spwt1llc8vq5n1mofaz96j6bbgxaf8wbz7c
PFE
1 Jun 24
.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its
j5urqwkea45npcg7pzalaj1u8a5181qdv762q
LLY
1 Jun 24
risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings
1njk31au2zeservzadfc7bs p5d0jx8ck1fac
CGEM
1 Jun 24
"Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from
mee ld837lfb6xbjsx8523hug4a3tgn9wz6fkt1
GL
31 May 24
July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark
mgtmm597jypmh8im1utx2ensq4de2arcbj95govn9pc7lkmp90uqc87
CC
31 May 24
in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023 and our
vk1pmufqmcojg8masy0xxpkdg2g8qjuowvfk5 uhowqcsgbdk342hg3
MDRX
31 May 24
procedures. As a result, Veradigm would not meet the deadline to file its annual report on Form 10-K. On this news, the price of Veradigm stock fell